Guidelines on PML risk stratification and diagnosis in patients with MS treated with natalizumab: so far so good?
MS Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.
Mike P
MP
Wattjes
Department of Neurology, Medical Faculty, Heinrich Heine University Hospital, Düsseldorf, Germany.
Clemens
C
Warnke
D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000175:diagnosis*; D000069442:Natalizumab / Q000009:adverse effects*
D007166:Immunosuppressive Agents; D000069442:Natalizumab
MRI; MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY